Concepedia

Eric von Hofe

EV

32

Publications

1.5K

Citations

20

H-Index

1986

Active since

Affiliations

Antigen Express (United States)(Current)

St Savas Hospital

The University of Texas MD Anderson Cancer Center

DecImmune Therapeutics (United States)

University of Antwerp

Eric von Hofe is an author at Antigen Express (United States) specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

1986–2023

32

Publications

32

Inhibition of tumorigenesis by a cytosine–DNA, methyltransferase, antisense oligodeoxynucleotide

Shyam Ramchandani, A. Robert MacLeod, Marc Pinard et al. · Proceedings of the National Academy of Sciences · 1997 · 172 citations · Full text

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/<i>neu</i>Peptide (AE37) Vaccine

Jarrod P. Holmes, Linda C. Benavides, Jeremy D. Gates et al. · Journal of Clinical Oncology · 2008 · 136 citations

Assessment of Bet v 1-Specific CD4+ T Cell Responses in Allergic and Nonallergic Individuals Using MHC Class II Peptide Tetramers

Laurence Van Overtvelt, Erik Wambre, Bernard Maillère et al. · The Journal of Immunology · 2008 · 121 citations · Full text

O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts

S. Clifford Schold, Thomas P. Brent, Eric von Hofe et al. · Journal of neurosurgery · 1989 · 120 citations

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Elizabeth A. Mittendorf, Alexandros Ardavanis, James T. Symanowski et al. · Annals of Oncology · 2016 · 107 citations · Full text

, , +10

Rows per page

1–5 of 32